Nykode Therapeutics Stock
Stocks
VACC
NO0010714785
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Oslo Bors
10:45:00 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 3.610 NOK | 0.00% |
|
-9.07% | +49.67% |
| 08-28 | Nykode Therapeutics Raises NOK286 Million via Share Placement | MT |
| 08-27 | ABG Sundal Collier raises the target price for Nykode Therapeutics to 7.0 Norwegian kroner (4.5), reiterates buy | FW |
| Market Cap | 1.18B 124M 109M 103M 93.4M 175M 11.89B 176M 1.23B 476M 6.07B 465M 455M 19.49B | P/E 2026 * |
-5.49x | P/E 2027 * | 68.8x |
|---|---|---|---|---|---|
| Enterprise Value | 690M 72.5M 63.76M 60.3M 54.69M 103M 6.96B 103M 722M 279M 3.55B 272M 266M 11.41B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 2.55x |
| Free-Float |
76.21% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Oslo Bors
| VACC | Real-time | |
CBOE
| Real-time | ||
|
Börse Stuttgart
| 5VB | Delayed | |
|
Nasdaq Stockholm
| NYKD O | Delayed | |
|
Deutsche Boerse AG
| 5VB | Delayed | |
|
OTC Markets
| VACBF | Delayed | |
|
Boerse Muenchen
| 5VB | Real-time | |
|
CBOE
| Real-time |
Last Transcript: Nykode Therapeutics
| 1 week | -9.07% | ||
| Current month | -15.85% | ||
| 1 month | -16.05% | ||
| 3 months | +11.25% | ||
| 6 months | +21.71% | ||
| Current year | +49.67% |
| 1 week | 3.5 |  | 4.06 |
| 1 month | 3.5 | | 4.37 |
| Current year | 2.21 | | 5.2 |
| 1 year | 1.58 | | 5.2 |
| 3 years | 1.44 | | 24.3 |
| 5 years | 1.44 | | 85.3 |
| 10 years | 1.44 | | 93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Engsig
CEO | Chief Executive Officer | 54 | 2018-12-31 |
| President | 49 | 2016-12-31 | |
Harald Gurvin
DFI | Director of Finance/CFO | 51 | 2021-05-02 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | - | |
Trygve Lauvdal
BRD | Director/Board Member | 57 | - |
Susanne Stuffers
CHM | Chairman | 45 | 2025-04-22 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/27/25 | Buy | Company | 3,000,000 | 0.9187% | ||
| 12/20/24 | Buy | Director | 100,000 | 0.0306% | ||
| 12/20/24 | Sell | Director | 100,000 | 0.0306% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -9.07% | +121.34% | -84.64% | 134M | |
| -0.37% | -3.67% | +57.21% | +87.75% | 72.26B | |
| -0.07% | -2.70% | +37.74% | +86.90% | 60.24B | |
| -0.84% | +0.47% | +33.59% | +15.88% | 27.73B | |
| -0.14% | -2.75% | -14.13% | +356.79% | 25.73B | |
| +0.57% | +1.10% | +1.02% | -2.89% | 24.75B | |
| +1.10% | +1.86% | +25.07% | -7.59% | 20.74B | |
| -1.70% | +0.43% | +150.24% | +323.16% | 15.06B | |
| +0.36% | +2.01% | +49.51% | +160.70% | 14.41B | |
| +4.00% | -3.39% | -4.44% | +518.28% | 14.23B | |
| Average | +0.28% | -0.45% | +45.71% | +145.43% | 27.53B | |
| Weighted average by Cap. | +0.05% | -1.08% | +37.96% | +129.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 214M 22.45M 19.74M 18.67M 16.93M 31.8M 2.15B 31.98M 224M 86.32M 1.1B 84.27M 82.45M 3.53B |
| Net income | -211M -22.2M -19.53M -18.47M -16.75M -31.45M -2.13B -31.64M -221M -85.39M -1.09B -83.36M -81.55M -3.49B | 11.3M 1.19M 1.04M 987K 895K 1.68M 114M 1.69M 11.82M 4.56M 58.14M 4.46M 4.36M 187M |
| Net Debt | -489M -51.32M -45.14M -42.68M -38.71M -72.7M -4.93B -73.13M -511M -197M -2.51B -193M -189M -8.08B | -634M -66.61M -58.58M -55.4M -50.24M -94.36M -6.39B -94.91M -663M -256M -3.26B -250M -245M -10.48B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-28 | NOK 3.610 | -7.55% | 3,322,565 |
| 26-09-25 | NOK 3.905 | +2.36% | 1,455,737 |
| 26-09-24 | NOK 3.815 | -3.05% | 1,436,951 |
| 26-09-23 | NOK 3.935 | -2.36% | 629,340 |
| 26-09-22 | NOK 4.030 | +1.51% | 896,598 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VACC Stock
Select your edition
All financial news and data tailored to specific country editions
